Staidson (300204.SZ): Bojianing (pomiteplase alfa for injection) application for new drug clinical trial for additional indication has been accepted

Zhitong Finance APP News, Staidson (300204.SZ) announced that recently, its subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. (hereinafter referred to as "Beijietai") received the administrative licensing document "Notice of Acceptance" from the National Medical Products Administration. The National Medical Products Administration agreed to accept the clinical trial application submitted by Beijietai for the new indication of Porcine-derived Fibrinogenase for Injection, with acceptance number: CXSL2601019, application stage: clinical; indication: treatment of major surgical bleeding.